Does salmon calcitonin cause cancer? A review and meta-analysis

Osteoporosis International

Volumn 27, Issue 1, 2016, Pages 13-19

  Wells, G ^a   Chernoff, J ^b   Gilligan, J P ^c   Krause, D S ^c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b FOX CHASE CANCER CENTER   (United States)

^c Tarsa Therapeutics Inc   (United States)

Author keywords

Cancer; Meta analysis; Review; Salmon calcitonin

Indexed keywords

SALCATONIN; BONE DENSITY CONSERVATION AGENT; CALCITONIN;

AGGRESSIVENESS; CANCER RISK; CELL PROLIFERATION; DISEASE ASSOCIATION; HUMAN; LNCAP CELL LINE; NEOPLASM; NONHUMAN; OSTEOSARCOMA CELL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; ANIMAL; CHEMICALLY INDUCED; META ANALYSIS; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84954392480     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3339-z     Document Type: Review

References (39)

1. Hirsch PF, Baruch H (2003) Is calcitonin an important physiologic substance? Endocrine 21:201–08
2. Martin TJ, Sims NA (2015) Calcitonin physiology, saved by a lysophospholipid. J Bone Miner Res 30:212–15
3. Mori I, Ishii A, Nakamura M et al (2006) Expression and cellular localization of calcitonin receptor: RT-PCR and in situ hybridization studies. Cell Mol Biol (Noisy-le-grand) 52:9–13
4. Niall HD, Keutmann HT, Copp DH, Potts JT (1969) Amino acid sequence of salmon ultimobranchial calcitonin. Proc Natl Acad Sci U S A 64:771–8
5. Miacalcin® nasal spray [package insert]. Novartis Pharmaceuticals Corp. East Hanover, New Jersey 07936; March 2014
6. CHMP Referral Assessment Report Procedure number: EMEA/H/A-31/1291 24 July 2012
7. U.S. Food and Drug Administration. Background document for meeting of Advisory Committee for reproductive health drugs and drug safety and risk management advisory committee. March 5, 2013. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341779.pdf
8. Karsdal MA, Byrjalsen I, Alexandersen P et al (2015) Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthr Cart 23:532–43
9. Hay D, Poyner DR, Quirion R (2008) Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol Rev 60:143–145
10. Findlay D, Sexteon PM (2004) Calcitonin. Growth Factors 22:217–24
11. Houslay MD, Kolch W (2000) Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58:659–68
12. Ng KW, Livesey SA, Larkins RG, Martin TJ (1983) Calcitonin effects on growth and on selective activation of type II isoenzyme of cyclic adenosine 3′5′-monophosphate-dependent protein kinase in T47D human breast cancer cells. Cancer Res 43:794–800
13. Blok LJ, de Ruiter PE, Brinkmann AO (1998) Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 37:3850–57
14. Chien J et al (2001) Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Mol Cell Endocrinol 181:69–79
15. Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV (2005) Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res 25:2075–2083
16. Sabbisetti VS et al (2005) Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer 117:551–560
17. Shah GV et al (1994) Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates and cytoplasmic Ca2+ transients. Endocrinology 134:596–602
18. Chigurupati S, Kulkarni T, Thomas S, Shah G (2005) Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 65:8519–29
19. Shah GV et al (2008) Calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways. Endocr Relat Cancer 15:953–64
20. Macchia V, Di Carlo A, De Luca C, Mariano A (2001) Effects of cyclic adenosine-monophosphate on growth and PSA secretion of human prostate cancer cell line. Int J Oncol 18:1071–76
21. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA (1997) Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30:183–187
22. Segawa N et al (2001) Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells. Cancer Res 61:6060–63
23. Nakamura M, Han B, Nishishita T, Bai Y, Kakudo K (2007) Calcitonin targets extracellular signal regulated kinase signaling pathway in human cancers. J Mol Endocrinol 39:375–384
24. Tsagaraki I, Phenkos C, Tsilibary E et al (2013) Calcitonin-induced NF-KB activation up-regulates fibronectin expression in MG63 osteosarcoma cells. Anticancer Res 33:4901–06
25. Sondergaard BC, Catala-Lehnen HAK et al (2012) Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthr Cartil 20:136–43
26. Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612
27. Ronckers CM, McCarron P, Ron E (2005) Thyroid carcinoma and multiple tumors in the SEER cancer registries. Int J Cancer 117:281–88
28. Heep M et al (2012) Calcitonin use and risk of malignancy: a meta-analysis of 17 RCTs in patients with osteoporosis. Presented at the American Society of Bone and Mineral Research Annual Meeting 2012. Abstract 1234, October 15, 2012
29. Novartis Pharmaceuticals. Briefing book prepared for the joint meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee. 2013 Accessed at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341781.pdf
30. Chesnut CH, Silverman S, Andriano K et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fracture study. Am J Med 109:267–76
31. Binkley N, Bolognese M, Sidorowicz-Bialynicka A et al (2012) A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J Bone Miner Res 27:1821–29
32. Binkley N, Bone H, Gilligan JP, Krause D (2014) Efficacy and safety of oral recombinant salmon calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos Int 25:2649–56
33. Krause D, Hernandez NAS, Vitagliano M, et al (2012) One year use of oral recombinant salmon calcitonin is not associated with increased risk of cancer. Presented at the American Society of Bone and Mineral Research Annual Meeting 2013. Presentation Number LB-MO17
34. Overman RA, Borse M, Gourlay ML (2013) Salmon calcitonin use and associated cancer risk. Ann Pharmacother 47:1675–84
35. Sun L, Lin M, Muo C et al (2014) Calcitonin nasal spray and increased cancer risk: a population based nested case-control study. J Clin Endocrinol Metab 99:4259–64
36. Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300
37. Edwards I (2012) Considerations on causality in pharmacovigilance. Int J Risk Saf Med 24:41–54
38. Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone 57(2):423–428
39. Black D, Bauer D, Schwartz A, Cummings S, Rosen C (2012) Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 366(22):2051–3